| Assay ID | Title | Year | Journal | Article |
|---|
| AID1324655 | Antiproliferative activity against human Ramos cells after 48 hrs by CCK-8 assay | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1869077 | Inhibition of BTK T474I mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. |
| AID1820501 | Inhibition of BTK phosphorylation in human whole blood assessed as reduction in BTK phosphorylation incubated for 30 mins | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
| Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. |
| AID1468817 | Selectivity ratio of IC50 for recombinant human full length His-tagged STK16 to IC50 for recombinant human full length His-tagged BTK | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1469889 | Inhibition of recombinant human N-terminal GST-tagged JAK3 (781 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescen | | | |
| AID1468808 | Inhibition of recombinant human cytoplasmic GST-tagged LTK expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1650542 | Inhibition of recombinant human N-terminal GST-tagged JAK1 (850 to 1154 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1809419 | Inhibition of Btk (unknown origin) assessed as ratio of Kinact/Ki | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
| Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( |
| AID1324661 | Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1484561 | Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1869074 | Inhibition of His-tagged full-length recombinant wild-type human BTK (Ala2 to Ser659 residues) expressed in baculovirus infected insect cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. |
| AID1553424 | Cytotoxicity against human BJ cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1426144 | Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 94.3%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1469895 | Ratio of Kinact to Ki for full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells | | | |
| AID1334888 | Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 55.07 %) | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1426145 | Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.7%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1553423 | Cytotoxicity against human HELF cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1401319 | Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.0%) | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1650556 | Metabolic stability in human liver microsomes assessed as compound remaining at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1468806 | Inhibition of recombinant human catalytic GST-tagged JAK3 expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1334877 | Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells measured after 60 mins by ADP-Glo kinase assay | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1869073 | Inhibition of BTK T474M mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. |
| AID1650554 | Metabolic stability in human liver microsomes assessed as half life at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1553414 | Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1324656 | Inhibition of recombinant human N-terminal His-tagged BTK expressed in baculovirus infected sf9 cells using poly(4:1 Glu,Tyr) as substrate by ADP-Glo kinase assay | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1401320 | Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98.7%) | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1468807 | Inhibition of recombinant human cytoplasmic GST-tagged EGFR expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1484562 | Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1650550 | Antiproliferative activity against human Ramos cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1650541 | Inhibition of recombinant human His-tagged full length BTK expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1468805 | Inhibition of recombinant human full length His-tagged BLK expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1401311 | Antiproliferative activity against human NAMALWA cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1334900 | Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry (Rvb = 0.2 %) | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1650544 | Inhibition of recombinant human N-terminal His-tagged JAK3 (795 to 1124 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1469888 | Inhibition of full length recombinant human N-terminal GST-tagged BMX expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay | | | |
| AID1553407 | Antiproliferative activity against human Ramos cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553419 | Cytotoxicity against human A549 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1468804 | Inhibition of human full length GST-tagged TXK expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1650549 | Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1334897 | Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1468815 | Selectivity ratio of IC50 for human full length GST-tagged TXK to IC50 for recombinant human full length His-tagged BTK | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1426158 | Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 1.58%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1553409 | Cytotoxicity against human K562 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553408 | Antiproliferative activity against human Raji cells assessed as reduction in cell growth incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1650551 | Antiproliferative activity against human HEL cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1469887 | Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay | | | |
| AID1468809 | Inhibition of recombinant human cytoplasmic GST-tagged ERBB4 expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1484560 | Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1820500 | Inhibition of human BTK using fluorescein-labeled polyGAT peptide as substrate incubated for 30 mins by FRET assay | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
| Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. |
| AID1468811 | Selectivity ratio of IC50 for cytoplasmic recombinant human full length His-tagged BMX to IC50 for recombinant human full length His-tagged BTK | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1553417 | Cytotoxicity against human PC3 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553406 | Inhibition of human recombinant full length BTK expressed in baculovirus in Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate incubated for 1 hr by ADP-Glo assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1468802 | Inhibition of recombinant human full length His-tagged BTK expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1401318 | Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.5%) | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1553421 | Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1869076 | Inhibition of BTK C481R mutant (unknown origin) expressed in baculovirus infected Trichoplusia ni pro cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. |
| AID1426141 | Antiproliferative activity against human Ramos cells after 48 hrs by CCK-8 assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1553432 | Antitumor activity in human Ramos cells xenografted in NOD/SCID mouse assessed as reduction in tumor growth at 30 mg/kg/day, ip administered daily for 14 days | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1468814 | Selectivity ratio of IC50 for recombinant human cytoplasmic full length His-tagged TEC to IC50 for recombinant human full length His-tagged BTK | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1484563 | Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.2%) | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1334886 | Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 39.95 %) | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1468810 | Inhibition of recombinant human cytoplasmic full length His-tagged TEC expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1553413 | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1484554 | Antiproliferative activity against human Ramos cells over expressing BTK after 48 hrs by CCK-8 assay | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1357749 | Inhibition of LYN (unknown origin) | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. |
| AID1334878 | Antiproliferative activity against human Ramos cells measured after 48 hrs by CCK-8 assay | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1820499 | Inhibition of human BTK assessed as ratio of Kinact/Kt using fluorescein-labeled polyGAT peptide as substrate incubated for 30 mins by FRET assay | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
| Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. |
| AID1553411 | Cytotoxicity against human Jurkat cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1650555 | Metabolic stability in human liver microsomes assessed as intrinsic clearance at 0.2 uM incubated for 60 mins by UPLC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1426146 | Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1650552 | Antiproliferative activity against human JeKo1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1324660 | Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1426157 | Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 42.23%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1401307 | Inhibition of recombinant full-length N-terminal His-tagged human BTK expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1553420 | Cytotoxicity against human H1299 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553410 | Cytotoxicity against human KARPAS299 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553418 | Cytotoxicity against human HT-29 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1401309 | Antiproliferative activity against human Ramos cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1291431 | Inhibition of BTK (unknown origin) | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
| Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis. |
| AID1334879 | Antiproliferative activity against human Raji cells measured after 48 hrs by CCK-8 assay | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1401310 | Antiproliferative activity against human Raji cells after 72 hrs by CCK-8 assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1426147 | Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1401330 | Induction of apoptosis in human Ramos cells assessed as total apoptosis rate at 10 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1357747 | Inhibition of BTK (unknown origin) | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. |
| AID1820502 | Inhibition of CD69 in human whole blood preincubated for 30 mins followed by anti-human IgD stimulation and measured after 18 to 22 hrs by flow cytometry | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
| Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. |
| AID1553436 | Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Erk phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1484555 | Antiproliferative activity against human Raji cells over expressing BTK after 48 hrs by CCK-8 assay | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1869075 | Inhibition of BTK C481S mutant (unknown origin) expressed in baculovirus infected Sf9 insect cells incubated for 30 mins in presence of ATP by Microfluidic chip based mobility shift assay | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
| Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance. |
| AID1324663 | Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 56.19%) | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1484553 | Inhibition of human recombinant full-length N-terminal His-tagged BTK expressed in baculovirus infected Sf9 insect cells after 60 mins by ADP-Glo kinase assay | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. |
| AID1469893 | Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells assessed as inactivation rate using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate additi | | | |
| AID1553437 | Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in Akt phosphorylation at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1334898 | Induction of apoptosis in human Ramos cells assessed as late apoptotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1401308 | Inhibition of recombinant N-terminal GST-tagged human JAK3 (781 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly(4:1 Glu,Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1553422 | Cytotoxicity against human HEF cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1553415 | Cytotoxicity against human 786-O cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1324662 | Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 48 hrs by annexin V/FITC propidium iodide staining based flow cytometry relative to control | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1357748 | Inhibition of TEC (unknown origin) | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. |
| AID1553416 | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1426156 | Cell cycle arrest in human Ramos cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 56.19%) | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1553412 | Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1324665 | Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 1.58%) | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1650545 | Inhibition of recombinant human N-terminal GST-tagged TYK2 (871 to 1187 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1468816 | Selectivity ratio of IC50 for recombinant human catalytic GST-tagged JAK3 to IC50 for recombinant human full length His-tagged BTK | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1468764 | Inhibition of recombinant human cytoplasmic His-tagged ERBB2 expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1426142 | Antiproliferative activity against human Raji cells after 48 hrs by CCK-8 assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1469890 | Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo | | | |
| AID1650543 | Inhibition of recombinant human N-terminal His-tagged JAK2 (826 to 1132 residues) expressed in baculovirus expression system using Ulight-Poly GT as substrate incubated for 2 hrs by Lanthascreen TR-FRET assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1553425 | Cytotoxicity against human MCF10A cells assessed as reduction in cell viability at 0.1 to 40 uM incubated for 48 hrs by MTS assay | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1291432 | Antiproliferative activity against B cells (unknown origin) | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
| Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis. |
| AID1553435 | Inhibition of BTK in anti-IgM-stimulated human Ramos cells assessed as reduction in autophosphorylation at Y223 residue at 10 uM incubated for 4 hrs followed by anti-IgM stimulation for 30 mins by Western blot analysis | 2019 | Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
| Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. |
| AID1334890 | Cell cycle arrest in human Ramos cells assessed as accumulation at G2/M phase at 10 uM measured after 48 hrs by propidium iodide based flow cytometry (Rvb = 4.98 %) | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1468803 | Inhibition of cytoplasmic recombinant human full length His-tagged BMX expressed in baculovirus at 1 uM by Z'-LYTE assay | 2018 | Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
| Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. |
| AID1654023 | Inhibition of recombinant human N-terminal GST-tagged JAK3 (781 to end residues) expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate incubated for 60 mins in presence of ATP by ADP-Glo kinase assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. |
| AID1334899 | Induction of apoptosis in human Ramos cells assessed as early apoptotic cells at 10 uM measured after 48 hrs by Annexin V-FITC/propidium iodide based flow cytometry relative to control | 2017 | Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
| Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. |
| AID1401317 | Induction of apoptosis in human Ramos cells assessed as necrotic cells at 10 uM after 72 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7%) | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. |
| AID1324658 | Antiproliferative activity against human Raji cells after 48 hrs by CCK-8 assay | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1469894 | Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo lumin | | | |
| AID1426139 | Inhibition of N-terminal His-tagged full length human recombinant BTK expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) peptide substrate incubated for 60 mins by ADP-Glo luminescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. |
| AID1324664 | Cell cycle arrest in human Ramos cells assessed as accumulation at S phase at 10 uM by propidium iodide staining based flow cytometry (Rvb = 42.23%) | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1324659 | Induction of apoptosis in human Ramos cells assessed as viable cells at 10 uM after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry relative to control | 2016 | ACS medicinal chemistry letters, Dec-08, Volume: 7, Issue:12
| Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a |
| AID1650553 | Antiproliferative activity against human OCI-LY10 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay | 2020 | Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
| Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |